CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

DISEASE CHARACTERISTICS: * Histologically confirmed refractory solid tumor and/or lymphoma * No brain metastases or primary CNS malignancies PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * More than 3 months Hematopoietic: * Granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin normal * ALT and AST less than 2.5 times normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance greater than 60 mL/min Cardiovascular: * No unstable or newly diagnosed angina pectoris * No myocardial infarction within the past 6 months * No New York Heart Association class II, III, or IV congestive heart failure Pulmonary: * No chronic obstructive lung disease requiring oxygen therapy Other: * No uncontrolled seizures * No concurrent acute critical illness * No serious untreated infection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 2 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior biologic therapy Chemotherapy: * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or carboplatin) * No concurrent cytotoxic chemotherapy Endocrine therapy: * At least 4 weeks since prior hormonal therapy * Concurrent luteinizing hormone-releasing hormone agonist required in patients with prostate cancer unless prior orchiectomy has been performed Radiotherapy: * At least 4 weeks since prior radiotherapy Surgery: * See Endocrine therapy * Prior surgery allowed Other: * Recovered from prior therapy * No concurrent anticonvulsants (e.g., phenobarbital, phenytoin, or carbamazepine) * No concurrent rifampin * No concurrent grapefruit juice